Trending...
- Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
- Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
Download
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
More on ncarol.com
- Miley Is Going by One Name. KayeDinero Just Put Her Birth Name in a Song
- Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
- Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
- Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
- TikTok's Song of Summer Is 15 Years Old. KayeDinero Is Betting on Memory Too
"Labcorp is the only reference laboratory to offer stinging insect (venom) component testing," said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic's esoteric testing unit. "The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy."
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
"It is very important to identify the specific insect species for effective therapy," said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. "Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients."
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
More on ncarol.com
- Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
- Google Mixed Up KayeDinero and Kayla Dinero. KayeDinero Brought Visual Receipts
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- Drake Brings Jimmy Brooks Back as KayeDinero Turns Banks Ave Into a Nighttime Visual
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
0 Comments
Latest on ncarol.com
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- KayeDinero Took Her Voice Off the Beat — And Says the Music Got More Personal
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- KayeDinero Didn't Stop Writing. She Stopped Putting Words on the Beat
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Before Python, There Was Chess: KayeDinero Makes Her Next Move With "Checkmate"
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
- Revenue Optics Names Prat Patibandla Director of Growth Marketing
- VMACS Offers Battery-Powered Heat & AC Systems for RVs and Vans
- Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
- JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
- Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
- Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
- Data Tiles Challenges the Data Product Status Quo Following Antwerp Summit
- Visit London Appoints The SEO Works for AI-First Search Strategy
- Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland